Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Jewett

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Brain, Behavior, and Immunity|November 23, 2020
The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's diseaseItzia Jimenez-Ferrer, Filip Bäckström, Alfredo Dueñas-Rey, et al.
European Urology Open Science|March 4, 2022
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 CountriesRachel Giles, Deborah Maskens, Robert Bick, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 19, 2009
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinomaWassim Kassouf, Robert Siemens, Christopher Morash, et al.
Cancer|June 19, 2009
Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic OncologyYair Lotan, Ashish M Kamat, Michael P Porter, et al.
Urologic Oncology|February 21, 2017
Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7]Ross Mason, Anil Kapoor, Zhihui Liu, et al.
Molecular Oncology|June 9, 2015
An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathwaysSamantha Jane Wala, Jason Raj Karamchandani, Rola Saleeb, et al.
Cancer|April 21, 2012
Utility of serum tumor markers during surveillance for stage I seminomaDanny Vesprini, Peter Chung, Shaun Tolan, et al.
Urologic Oncology|June 27, 2016
The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information SystemRoss Mason, Anil Kapoor, Zhihui Liu, et al.
BJU International|January 6, 2025
'BJUI Clinical Dilemma': the incidental small renal mass in a solitary kidneyBruce Gao, Pratik Kanabur, Riccardo Campi, et al.
The Journal of Molecular Diagnostics : JMD|January 4, 2015
miR-210 is a prognostic marker in clear cell renal cell carcinomaSara Samaan, Heba W Z Khella, Andrew Girgis, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Brain, Behavior, and Immunity|November 23, 2020
The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's diseaseItzia Jimenez-Ferrer, Filip Bäckström, Alfredo Dueñas-Rey, et al.
European Urology Open Science|March 4, 2022
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 CountriesRachel Giles, Deborah Maskens, Robert Bick, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 19, 2009
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinomaWassim Kassouf, Robert Siemens, Christopher Morash, et al.
Cancer|June 19, 2009
Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic OncologyYair Lotan, Ashish M Kamat, Michael P Porter, et al.
Urologic Oncology|February 21, 2017
Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7]Ross Mason, Anil Kapoor, Zhihui Liu, et al.
Molecular Oncology|June 9, 2015
An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathwaysSamantha Jane Wala, Jason Raj Karamchandani, Rola Saleeb, et al.
Cancer|April 21, 2012
Utility of serum tumor markers during surveillance for stage I seminomaDanny Vesprini, Peter Chung, Shaun Tolan, et al.
Urologic Oncology|June 27, 2016
The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information SystemRoss Mason, Anil Kapoor, Zhihui Liu, et al.
BJU International|January 6, 2025
'BJUI Clinical Dilemma': the incidental small renal mass in a solitary kidneyBruce Gao, Pratik Kanabur, Riccardo Campi, et al.
The Journal of Molecular Diagnostics : JMD|January 4, 2015
miR-210 is a prognostic marker in clear cell renal cell carcinomaSara Samaan, Heba W Z Khella, Andrew Girgis, et al.
Pageof 8